Results 101 to 110 of about 4,368 (201)

Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis

Diabetology & Metabolic Syndrome
Objective To assess the effects of finerenone and glucagon-like peptide 1 receptor agonists (GLP1-RA) on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM), and the relative cardiovascular benefits in patients with or ...
Xia Gu, Shimin Jiang, Yue Yang, Wenge Li
doaj   +1 more source

Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective

BMJ Public Health
Introduction One in three patients with type 2 diabetes (T2D) suffers from any stage of chronic kidney disease (CKD), a chronic illness associated with a high global burden that impacts not only the healthcare system but also societal costs.
Maarten J Postma, Stephan J L Bakker, Sara Wilhelmien Quist, Jeanni van Loon, Michal Pochopién, Jeroen Paulissen   +5 more
doaj   +1 more source

Finerenone: a game changer for chronic kidney disease patients with type 2 diabetes

Journal of the Pakistan Medical Association
Dear Editor, Type 2 diabetes or (T2D) is characterized by the elevated blood glucose levels resulting from impaired beta-cell function and insulin resistance.
Fizzah Ikram Ul Haq, Aaitain Ikram Ul Haq   +1 more
doaj   +1 more source

Effects of finerenone on sudden death across the cardio-kidney-metabolic landscape: a FINE-HEART analysis [PDF]

International audienceBACKGROUNDThe nonsteroidal mineralocorticoid receptor antagonist finerenone has been shown to improve cardiovascular and kidney outcomes in patients with cardio-kidney-metabolic (CKM) syndrome, but its effects on sudden death (SD ...
Foà, Alberto, Zannad, Faiez, Lage, Andrea, Filippatos, Gerasimos, Solomon, Scott, D, Anker, Stefan, D, Pabon, Maria, A, Shah, Sanjiv, J, Agarwal, Rajiv, Vaduganathan, Muthiah, Claggett, Brian, L, Henderson, Alasdair, Rossing, Peter, Senni, Michele, Jhund, Pardeep, S, Ruilope, Luis, M, Lam, Carolyn S.P., McMurray, John J.V., Brinker, Meike, Voors, Adriaan, A, Hofmeister, Lucas, Miao, Zi Michael, Desai, Akshay, S, Pitt, Bertram, Solomon, Scott D., Voors, Adriaan A., Shah, Sanjiv J., Ruilope, Luis M., Anker, Stefan D., Pabon, Maria A., Claggett, Brian L., De Sanctis, Yoriko, Desai, Akshay S., Jhund, Pardeep S.   +33 more
core   +1 more source

Finerenone in kidney transplantation: an underinvestigated agent: review of available evidence, existing gaps, and future directions

Clinical Transplantation and Research
Emerging data on finerenone have drawn significant interest from nephrologists and cardiologists for its clinical potential in patient management. Its nonsteroidal structure, greater receptor selectivity, and reduced risk of hyperkalemia make it a ...
Muhammad Abdul Mabood Khalil, Nihal Mohammed Sadagah, Muhammad Shahab Uddin Khalil, Hideki Ishida, Jackson Tan, Salem H Al-Qurashi   +5 more
doaj   +1 more source

Risk of nephrolithiasis with finerenone versus other chronic kidney disease medications: a comparative real-world evidence study

Scientific Reports
Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has shown renoprotective benefits for chronic kidney disease (CKD) in people with type 2 diabetes (T2DM); however, its impact on nephrolithiasis remains unexplored.
Yi-Hong Chen, Tung-Liang Hwang, Ze-Hong Lu, Chan-Jung Liu   +3 more
doaj   +1 more source

Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation

Nature Communications
The comparative effectiveness of finerenone and spironolactone in chronic kidney disease (CKD) with type 2 diabetes (T2D) remains unclear. Here we show, using a target trial emulation on global real-world data from TriNetX, outcomes among 2268 propensity
Chung-An Wang, Hsuan-Wen Lai, Jui-Yi Chen, Wei-Jie Wang, Li-Chun Lin, Yen-Ling Chiu, Chung-Yi Cheng, Vin-Cent Wu   +7 more
doaj   +1 more source

A Trial of Finerenone in a Patient with Primary Aldosteronism

Kidney and Blood Pressure Research
Introduction: Primary aldosteronism (PA), a common secondary cause of arterial hypertension, is treated either surgically or pharmacologically with mineralocorticoid receptor antagonists (MRAs). These drugs, while effective, can cause allergic reactions and have side effects, including menstrual cycle disorders in women.
openaire   +3 more sources

Finerenone Alleviates Cardiac Microvascular Injury and Neutrophil Extracellular Traps Formation in Diabetic Cardiomyopathy via Regulating AKT1 Phosphorylation. [PDF]

Acta Physiol (Oxf)
Li S, Zhang H, Liu M, Zhu W, Yan X, Qiu W, Tian Y, Lian X, Lu D, Chen Z, Chen C, Chen Y, Qian J.   +12 more
europepmc   +1 more source

Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis. [PDF]

Eur Heart J
Lund LH, Pitt B.
europepmc   +1 more source